IN2014DN07509A - - Google Patents

Info

Publication number
IN2014DN07509A
IN2014DN07509A IN7509DEN2014A IN2014DN07509A IN 2014DN07509 A IN2014DN07509 A IN 2014DN07509A IN 7509DEN2014 A IN7509DEN2014 A IN 7509DEN2014A IN 2014DN07509 A IN2014DN07509 A IN 2014DN07509A
Authority
IN
India
Prior art keywords
independently
optionally substituted
therapy
halogen
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
Stephen Joseph Shuttleworth
Franck Alexandre Silva
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of IN2014DN07509A publication Critical patent/IN2014DN07509A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN7509DEN2014 2012-03-08 2013-03-08 IN2014DN07509A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1204125.7A GB201204125D0 (en) 2012-03-08 2012-03-08 Compounds
PCT/GB2013/050583 WO2013132270A1 (fr) 2012-03-08 2013-03-08 Inhibiteurs de phosphoinositide 3-kinase

Publications (1)

Publication Number Publication Date
IN2014DN07509A true IN2014DN07509A (fr) 2015-04-24

Family

ID=46026238

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7509DEN2014 IN2014DN07509A (fr) 2012-03-08 2013-03-08

Country Status (6)

Country Link
US (2) US9663487B2 (fr)
EP (1) EP2822943B1 (fr)
CN (1) CN104254532A (fr)
GB (1) GB201204125D0 (fr)
IN (1) IN2014DN07509A (fr)
WO (1) WO2013132270A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021038A1 (fr) 2009-08-20 2011-02-24 Karus Therapeutics Limited Composés hétérocycliques tricycliques en tant qu'inhibiteurs de phosphoinositide 3-kinase
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
ES2672701T3 (es) 2012-11-07 2018-06-15 Karus Therapeutics Limited Nuevos inhibidores de histona deacetilasa y su uso en terapia
CA2889905A1 (fr) 2012-11-08 2014-05-15 Rhizen Pharmaceuticals Sa Compositions pharmaceutiques contenant un inhibiteur de pde4 et un inhibiteur de pi3 kinase delta ou un double inhibiteur de pi3 kinase delta et gamma
KR20160007577A (ko) 2013-05-10 2016-01-20 카루스 떼라퓨틱스 리미티드 신규한 히스톤 디아세틸라제 억제제들
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
TW201940483A (zh) 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶2介導的傳訊之抑制劑
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CA2414468A1 (fr) * 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones et leur utilisation comme inhibiteurs des proteine kinases
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7799775B2 (en) 2004-02-26 2010-09-21 Aska Pharmaceutical Co., Ltd. Pyrimidine derivatives
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
RU2435769C2 (ru) * 2005-05-20 2011-12-10 Вертекс Фармасьютикалз Инкорпорейтед Пирролопиридины, полезные в качестве ингибиторов протеинкиназы
JP2009523812A (ja) 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
RU2008141356A (ru) 2006-04-26 2010-06-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные пиримидина в качестве ингибиторов фосфатидилинозитол-3-киназы (pi3k)
KR101402474B1 (ko) 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
CA2669399A1 (fr) 2006-11-13 2008-05-29 Eli Lilly & Co. Thienopyrimidinones destinees au traitement de troubles inflammatoires et de cancers
CN101663276A (zh) * 2007-01-31 2010-03-03 沃泰克斯药物股份有限公司 用作激酶抑制剂的2-氨基吡啶衍生物
EP2121613A2 (fr) * 2007-01-31 2009-11-25 Vertex Pharmaceuticals, Inc. Inhibiteurs de kinase
US20100063032A1 (en) 2007-03-28 2010-03-11 Debenham John S Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
JP2010529031A (ja) 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害剤としてのナフチリジン誘導体
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
CA2732087A1 (fr) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Naphtyridines substituees et leur utilisation en tant que medicaments
WO2010037765A2 (fr) 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2011012883A1 (fr) 2009-07-29 2011-02-03 Karus Therapeutics Limited Dérivés de la benzo[e][1,3]oxazin-4-one en tant qu'inhibiteurs de la phosphoinositide 3‑kinase
WO2011021038A1 (fr) 2009-08-20 2011-02-24 Karus Therapeutics Limited Composés hétérocycliques tricycliques en tant qu'inhibiteurs de phosphoinositide 3-kinase
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
LT3333161T (lt) 2011-07-27 2020-05-11 Astrazeneca Ab 2-(2,4,5-pakeistieji-anilino)pirimidino dariniai kaip egfr moduliatoriai, naudingi vėžio gydymui
WO2013017480A1 (fr) 2011-07-29 2013-02-07 Cellzome Limited Dérivés de pyrazolo[4,3-c]pyridine en tant qu'inhibiteurs de jak
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
JP6430390B2 (ja) 2012-11-20 2018-11-28 ジェネンテック, インコーポレイテッド T790mを含むegfr変異体の阻害剤としてのアミノピリミジン化合物
KR20160007577A (ko) 2013-05-10 2016-01-20 카루스 떼라퓨틱스 리미티드 신규한 히스톤 디아세틸라제 억제제들
WO2014210354A1 (fr) 2013-06-28 2014-12-31 Genentech, Inc. Composés d'azaindazole en tant qu'inhibiteurs de la t790m contenant des mutants de l'egfr
ES2818933T3 (es) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
CN104254532A (zh) 2014-12-31
US20180072699A1 (en) 2018-03-15
EP2822943A1 (fr) 2015-01-14
EP2822943B1 (fr) 2018-10-03
US9663487B2 (en) 2017-05-30
WO2013132270A1 (fr) 2013-09-12
US10035785B2 (en) 2018-07-31
GB201204125D0 (en) 2012-04-25
US20150080395A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
IN2014DN07509A (fr)
CA2875877C (fr) Inhibiteurs syk
TN2012000401A1 (en) Heterocyclic compound
NZ705705A (en) Ret inhibitor
PH12014500599B1 (en) Protein kinase inhibitors
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
PH12014501719A1 (en) Pyridone derivatives
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
IN2014MN02598A (fr)
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
PH12013502434A1 (en) Substituted pyridopyrazines as novel syk inhibitors
GB201209587D0 (en) Therapeutic compounds
MY172422A (en) Pyrazole compound and pharmaceutical use thereof
MY170262A (en) Dicarboxylic acid compound
MX2013005819A (es) Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.
MX2014015345A (es) Inhibidores piranopiridona de tanquirasa.
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
MY163185A (en) 2-methoxy-pyridin-4-yl derivatives
MX2015002705A (es) Compuestos de piridinona para usarse en terapia fotodinamica.
CY1117011T1 (el) Παραγωγα αζολιου
MX358151B (es) Derivado de sitaxentan.
IN2014CN04922A (fr)
MY173812A (en) 2-pyridone compound